WO2012027473A3 - Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens - Google Patents

Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens Download PDF

Info

Publication number
WO2012027473A3
WO2012027473A3 PCT/US2011/048971 US2011048971W WO2012027473A3 WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3 US 2011048971 W US2011048971 W US 2011048971W WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
alphavirus
vectored
immunogenic compositions
protein antigens
Prior art date
Application number
PCT/US2011/048971
Other languages
French (fr)
Other versions
WO2012027473A2 (en
Inventor
Laura J. White
Robert Edward Johnston
Wahala M.P.B. Wahala
Aravinda De Silva
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Publication of WO2012027473A2 publication Critical patent/WO2012027473A2/en
Publication of WO2012027473A3 publication Critical patent/WO2012027473A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides an alphavirus vector comprising a dengue virus E protein antigen. Also provided are nucleic acids encoding or comprising the same. Also provided are multivalent compositions and pharmaceutical formulations comprising two or more alphavirus vectors or nucleic acids of the invention. The invention further provides methods of administering the alphavirus vectors, nucleic acids, compositions and/or pharmaceutical formulations to a subject, e.g., to induce an immune response against dengue virus, to treat dengue virus infection, to prevent dengue virus infection and/or to protect a subject from the effects of dengue virus infection.
PCT/US2011/048971 2010-08-24 2011-08-24 Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens WO2012027473A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37663010P 2010-08-24 2010-08-24
US61/376,630 2010-08-24

Publications (2)

Publication Number Publication Date
WO2012027473A2 WO2012027473A2 (en) 2012-03-01
WO2012027473A3 true WO2012027473A3 (en) 2012-08-16

Family

ID=45724045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048971 WO2012027473A2 (en) 2010-08-24 2011-08-24 Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens

Country Status (1)

Country Link
WO (1) WO2012027473A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032388A8 (en) 2013-06-26 2020-01-14 Univ North Carolina Chapel Hill glycoprotein and chimeric dengue virus, their uses, flavivirus particle, isolated nucleic acid molecule, and compositions
CN113736750B (en) * 2021-09-22 2023-03-31 中牧实业股份有限公司 Gata virus strain and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20090155301A1 (en) * 2006-02-27 2009-06-18 Mason Peter W Pseudoinfectious flavivirus and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20090155301A1 (en) * 2006-02-27 2009-06-18 Mason Peter W Pseudoinfectious flavivirus and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURA J. WHITE ET AL.: "An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice.", JOURNAL OF VIROLOGY., vol. 81, no. 19, 2007, pages 10329 - 10339 *

Also Published As

Publication number Publication date
WO2012027473A2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
WO2010037027A3 (en) Immunization of avians by mucosal administration of non-replicating vectored vaccines
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2006078294A3 (en) Alphavirus vectors for respiratory pathogen vaccines
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
DK2707393T3 (en) FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2010019262A3 (en) Polyvalent vaccine
EA201290675A1 (en) VACCINE VECTORS AND METHODS OF STRENGTHENING IMMUNE RESPONSES
WO2012021730A3 (en) Respiratory syncytial virus (rsv) vaccine
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2009080715A3 (en) Vaccines for malaria
WO2011159814A3 (en) Novel live recombinant booster vaccine against tuberculosis
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
NZ596223A (en) Combined measles-malaria vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820596

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820596

Country of ref document: EP

Kind code of ref document: A2